IONS - アイオニス・ファ―マシュ―ティカルズ （Ionis Pharmaceuticals Inc.）

In this piece, I evaluated two biotech stocks, Prometheus Biosciences (NASDAQ:RXDX) and Ionis Pharmaceuticals (NASDAQ:IONS), to determine which is …

https://www.investing.com/news/pro/ionis-pharmaceuticals-pt-lowered-to-61-at-piper-sandler-432SI-3011820

https://www.investing.com/news/pro/ionis-pharmaceuticals-pt-lowered-to-30-at-citi-432SI-3011608

Ionis Pharmaceuticals, Inc. (NASDAQ:NASDAQ:IONS) Q4 2022 Results Conference Call February 22, 2023 11:30 AM ETCompany ParticipantsWade Walke - SVP, IRBrett Monia - CEOBeth Hougen -…

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a fourth-quarter loss of $52…

Astrazeneca PLC found using ticker (AZN) have now 7 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 88 and 65 and has a mean target at 76.71. With the stocks previous close at 63.15 this would indicate that there is a potential upside of 21.5%. The day 50 moving average is 68.11 and the 200 day moving average is 64.1. The company has a market cap of $202,272m. You can visit the company''s website by visiting: https://www.astrazeneca.com The potential market cap would be $245,705m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Ionis Pharmaceuticals (IONS) announced Tuesday that the FDA issued Fast Track designation for its investigational therapy olezarsen for a rare form of dyslipidemia. Read the full story here.

In Thursday’s session, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) marked $39.38 per share, down from $39.75 in the previous session. While Ionis Pharmaceuticals Inc. has underperformed by -0.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IONS rose by 25.10%, with highs and lows ranging from $48.82 to […]

The FDA announced that a panel of experts is scheduled to discuss the approval for tofersen an ALS therapy Biogen (BIIB) and Ionis Pharma (IONS) has developed. Read the full story here.

https://www.investing.com/news/pro/ionis-pharmaceuticals-pt-raised-to-62-at-piper-sandler-432SI-2983700

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) price on Friday, December 23, fall -1.47% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $38.16. A look at the stock’s price movement, the close in the last trading session was $38.73, moving within a range at $37.69 and $38.525. The beta value … Is It Safe To Invest In Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Now? Read More »

Morgan Stanley has initiated Ionis Pharmaceuticals (IONS) with an equalweight rating saying it expects a competitive launch for eplontersen next year and pipeline data wont come until 2024.

https://www.investing.com/news/pro/morgan-stanley-downgrades-ionis-pharmaceuticals-to-equalweight-432SI-2968282

Astrazeneca PLC found using ticker (AZN) have now 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 88 and 64.5 and has a mean target at 75.5. Given that the stocks previous close was at 69.74 this indicates there is a potential upside of 8.3%. The day 50 moving average is 62.31 and the 200 day MA is 63.59. The company has a market cap of $218,593m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $236,647m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

According to data from Benzinga Pro, during Q3, Ionis Pharmaceuticals ''s (NASDAQ: IONS ) reported sales totaled $160.00 million. Despite a 55.3% increase in earnings, the company posted a loss of $46.99 million. Ionis Pharmaceuticals collected $134.00 million in revenue during Q2, but reported earnings showed a $105.14 million loss. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com